RECURSION PHARMACEUTICALS, INC. Operating Cash Flow
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Operating Cash Flow of -$187.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- RECURSION PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$105.95M.
- RECURSION PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$81.10M.
- RECURSION PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$46.07M.
- RECURSION PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$117.36M.
- RECURSION PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$371.81M.
- RECURSION PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$359.17M.
- RECURSION PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$287.78M.
- RECURSION PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$83.52M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$105.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$187.05M 10-Q · filed 2026-08-05 | -$233.12M derived: sum of 3 quarters · filed 2026-08-05 | -$350.48M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$81.10M 10-Q · filed 2026-05-06 | -$127.17M derived: sum of 2 quarters · filed 2026-05-06 | -$244.53M derived: sum of 3 quarters · filed 2026-05-06 | -$320.95M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$46.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$163.43M derived: sum of 2 quarters · filed 2026-02-25 | -$239.85M derived: sum of 3 quarters · filed 2026-08-05 | -$371.81M 10-K · filed 2026-02-25 |
| 2025-09-30 | -$117.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$193.78M derived: sum of 2 quarters · filed 2026-08-05 | -$325.74M 10-Q · filed 2025-11-05 | -$441.17M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$76.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$208.38M 10-Q · filed 2026-08-05 | -$323.81M derived: sum of 3 quarters · filed 2026-08-05 | -$383.03M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$131.96M 10-Q · filed 2026-05-06 | -$247.39M derived: sum of 2 quarters · filed 2026-05-06 | -$306.61M derived: sum of 3 quarters · filed 2026-05-06 | -$388.83M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$115.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$174.66M derived: sum of 2 quarters · filed 2026-02-25 | -$256.87M derived: sum of 3 quarters · filed 2026-02-25 | -$359.17M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$59.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$141.44M derived: sum of 2 quarters · filed 2025-11-05 | -$243.74M 10-Q · filed 2025-11-05 | -$317.82M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$82.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$184.52M 10-Q · filed 2025-08-05 | -$258.60M derived: sum of 3 quarters · filed 2026-02-25 | -$331.52M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$102.30M 10-Q · filed 2025-05-05 | -$176.38M derived: sum of 2 quarters · filed 2026-02-25 | -$249.30M derived: sum of 3 quarters · filed 2026-02-25 | -$316.76M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$74.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$147.00M derived: sum of 2 quarters · filed 2026-02-25 | -$214.46M derived: sum of 3 quarters · filed 2026-02-25 | -$287.78M 10-K · filed 2026-02-25 |
| 2023-09-30 | -$72.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$140.39M derived: sum of 2 quarters · filed 2024-11-06 | -$213.70M 10-Q · filed 2024-11-06 | -$258.45M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | -$67.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$140.78M 10-Q · filed 2024-08-08 | -$185.53M derived: sum of 3 quarters · filed 2025-02-28 | -$240.07M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | -$73.32M 10-Q · filed 2024-05-09 | -$118.06M derived: sum of 2 quarters · filed 2025-02-28 | -$172.60M derived: sum of 3 quarters · filed 2025-02-28 | -$234.23M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | -$44.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$99.29M derived: sum of 2 quarters · filed 2025-02-28 | -$160.91M derived: sum of 3 quarters · filed 2025-02-28 | -$83.52M 10-K · filed 2025-02-28 |
| 2022-09-30 | -$54.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$116.16M derived: sum of 2 quarters · filed 2023-11-09 | -$38.78M 10-Q · filed 2023-11-09 | -$99.93M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$61.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $15.77M 10-Q · filed 2023-08-08 | -$45.39M derived: sum of 3 quarters · filed 2024-02-29 | -$78.44M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $77.39M 10-Q · filed 2023-05-08 | $16.23M derived: sum of 2 quarters · filed 2024-02-29 | -$16.82M derived: sum of 3 quarters · filed 2024-02-29 | -$50.47M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$61.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$94.21M derived: sum of 2 quarters · filed 2024-02-29 | -$127.86M derived: sum of 3 quarters · filed 2024-02-29 | -$158.61M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$33.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$66.70M derived: sum of 2 quarters · filed 2022-11-08 | -$97.46M 10-Q · filed 2022-11-08 | -$88.88M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$33.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$64.41M 10-Q · filed 2022-08-09 | -$55.84M derived: sum of 3 quarters · filed 2023-02-27 | -$75.29M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$30.75M 10-Q · filed 2022-05-10 | -$22.18M derived: sum of 2 quarters · filed 2023-02-27 | -$41.64M derived: sum of 3 quarters · filed 2023-02-27 | -$58.34M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $8.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$10.88M derived: sum of 2 quarters · filed 2023-02-27 | -$27.58M derived: sum of 3 quarters · filed 2023-02-27 | -$45.40M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$19.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$36.16M derived: sum of 2 quarters · filed 2021-11-10 | -$53.97M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$16.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | -$34.52M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | -$17.82M 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | -$57.04M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |